Login to Your Account

U.S. Patent Disclosures

Tuesday, February 22, 2011
• Asuragen Inc., of Austin, Texas, has received notices of allowance for claims related to the use of mir-21 and mir-30a as diagnostics in lung cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription